loading
Structure Therapeutics Inc Adr stock is traded at $22.76, with a volume of 697.04K. It is down -4.02% in the last 24 hours and down -19.59% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$23.75
Open:
$23.77
24h Volume:
697.04K
Relative Volume:
0.83
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-10.25
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+8.39%
1M Performance:
-19.59%
6M Performance:
-40.28%
1Y Performance:
-44.73%
1-Day Range:
Value
$21.83
$23.77
1-Week Range:
Value
$19.61
$24.12
52-Week Range:
Value
$19.61
$62.74

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name
Name
Structure Therapeutics Inc Adr
Name
Phone
(628) 229-9277
Name
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Name
Employee
148
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GPCR's Discussions on Twitter

Compare GPCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GPCR
Structure Therapeutics Inc Adr
22.83 1.29B 0 -100.44M -105.32M -2.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.31 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
688.49 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.75 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.34 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.79 27.34B 3.30B -501.07M 1.03B -2.1146

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Initiated William Blair Outperform
Jan-08-25 Initiated Stifel Buy
Dec-04-24 Initiated H.C. Wainwright Buy
Sep-23-24 Initiated Morgan Stanley Overweight
May-21-24 Initiated JP Morgan Overweight
Apr-09-24 Initiated Cantor Fitzgerald Overweight
Oct-19-23 Initiated JMP Securities Mkt Outperform
Jul-27-23 Initiated Piper Sandler Overweight
May-25-23 Resumed Jefferies Buy
Feb-28-23 Initiated BMO Capital Markets Outperform
Feb-28-23 Initiated Guggenheim Buy
Feb-28-23 Initiated Jefferies Buy
Feb-28-23 Initiated SVB Securities Outperform
View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

pulisher
07:34 AM

Leerink cuts Structure Therapeutics target to $60, keeps outperform - Investing.com India

07:34 AM
pulisher
02:32 AM

Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at William Blair - Defense World

02:32 AM
pulisher
02:30 AM

Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

02:30 AM
pulisher
01:35 AM

Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29 - Defense World

01:35 AM
pulisher
Mar 01, 2025

Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Structure Therapeutics Advances in Obesity Treatment Pipeline - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings Beat - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Promising Potential of Structure Therapeutics’ Aleniglipron: A Compelling Buy Recommendation - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average Price Target from Brokerages - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week LowTime to Sell? - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Structure Therapeutics reports Q4 net loss $36.5M vs. net loss $24.5M last year - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4%Time to Sell? - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Handelsbanken Fonder AB Acquires Shares of 165,000 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

GPCR stock touches 52-week low at $20.11 amid market challenges By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

GPCR stock touches 52-week low at $20.11 amid market challenges - Investing.com India

Feb 26, 2025
pulisher
Feb 25, 2025

Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2%Here's Why - MarketBeat

Feb 25, 2025
pulisher
Feb 20, 2025

Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

GPCR Stock Hits 52-Week Low at $23.48 Amid Market Challenges - Investing.com Canada

Feb 19, 2025
pulisher
Feb 19, 2025

Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s What Happened - Defense World

Feb 19, 2025
pulisher
Feb 14, 2025

Why Structure Therapeutics Stock Was Stumbling This Week - The Globe and Mail

Feb 14, 2025
pulisher
Feb 14, 2025

abrdn plc Sells 45,695 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Feb 14, 2025
pulisher
Feb 11, 2025

Financial Fitness Check: Examining Structure Therapeutics Inc ADR (GPCR)’s Key Ratios - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

Spire Wealth Management Acquires Shares of 8,949 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.7%Should You Sell? - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

HSBC Securities Downgrades Morgan Stanley (MS) to a Hold from a Buy - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

JD.com Inc ADR (JD) receives an Outperform rating from Bernstein - Knox Daily

Feb 10, 2025
pulisher
Feb 07, 2025

Ratio Examination: Bausch Health Companies Inc (BHC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 07, 2025
pulisher
Feb 07, 2025

Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - MarketBeat

Feb 07, 2025
pulisher
Feb 07, 2025

Understanding the Recent Fluctuations of Structure Therapeutics Inc ADR’s (GPCR) Stock - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

CCG Wealth Management LLC Makes New $4.07 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 - Grand View Research

Feb 05, 2025
pulisher
Feb 03, 2025

Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - Defense World

Feb 03, 2025
pulisher
Feb 02, 2025

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 8.3%Still a Buy? - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Structure Therapeutics Lines Up Triple Conference Appearances: What's Next for GPCR? - StockTitan

Jan 30, 2025
pulisher
Jan 30, 2025

Fidelity Electric Vehicles and Future Transportation ETF (BATS:FDRV) Shares Up 0.5% – Still a Buy? - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

Liberty TripAdvisor (NASDAQ:LTRPA) Now Covered by Analysts at StockNews.com - Defense World

Jan 28, 2025
pulisher
Jan 26, 2025

ImmuPharma (LON:IMM) Trading 13.6% Higher – Here’s What Happened - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

JPMorgan Chase & Co. Has $1.31 Million Stock Holdings in iShares International Treasury Bond ETF (NASDAQ:IGOV) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

JPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

Jan 24, 2025
pulisher
Jan 24, 2025

Air T (NASDAQ:AIRT) Shares Cross Below 200-Day Moving Average – What’s Next? - Defense World

Jan 24, 2025
pulisher
Jan 24, 2025

JPMorgan Chase & Co. Acquires 25,500 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Jan 24, 2025

Structure Therapeutics Inc Adr Stock (GPCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.49
price down icon 3.91%
$23.04
price up icon 1.68%
$33.97
price up icon 1.09%
$19.98
price down icon 3.21%
biotechnology ONC
$244.72
price down icon 9.96%
$112.79
price down icon 0.24%
Cap:     |  Volume (24h):